Pancrelipase

Introduction Overview

Generic Name

pancrelipase

Brand Name

Zenpep

Dosage Form

Enteric-coated capsules and oral powder

Drug Class

Digestive enzymes

Pharmacokinetics

Absorption:
Pancrelipase, the active component of Zenpep, is a combination of naturally derived pancreatic enzymes including lipase, protease, and amylase. Because these enzymes are proteins, they are not systemically absorbed into the bloodstream in significant amounts when administered orally. Instead, their therapeutic activity is localized to the gastrointestinal tract, particularly in the small intestine where fat, protein, and carbohydrate digestion occurs. The enzymes are protected from gastric acidity by enteric-coated formulations, which prevent enzyme degradation in the stomach, allowing release at the higher pH of the duodenum and jejunum. Factors such as gastric pH, the presence of food, and coadministration of acid-suppressing agents can affect the release and local availability of the enzymes.

Distribution:
As pancrelipase acts locally within the lumen of the gastrointestinal tract, systemic distribution is minimal to negligible. There is no substantial absorption of enzymes into systemic circulation, thus avoiding systemic pharmacokinetic concerns such as volume of distribution or protein binding. This local action minimizes systemic side effects and drug interactions. However, care is taken to ensure enzymes reach the site of activity intact, which is achieved by enteric coating to withstand gastric acid and timely administration with meals.

Metabolism:
Pancrelipase is composed of exogenous digestive enzymes which mimic endogenous pancreatic enzymes. Their inactivation largely occurs through proteolytic degradation by gastric acid and proteases in the stomach if not adequately protected by enteric coating. Once released into the duodenum, the enzymes catalyze the breakdown of dietary lipids, proteins, and carbohydrates into absorbable units rather than undergoing metabolic biotransformation themselves. Any degradation or inactivation that occurs post-release is primarily through intestinal proteases.

Elimination:
Because pancrelipase enzymes are not absorbed systemically, they are not subject to renal or hepatic elimination. Instead, unmetabolized enzymes and their degradation products are eliminated via feces. The extent of enzyme activity elimination depends on gastrointestinal transit time and enzymatic stability within the intestinal milieu. There is minimal risk of accumulation, and dosing is usually adjusted based on digestion efficacy rather than pharmacokinetic elimination parameters.

Dosage Forms

Available Dosage Forms:
Zenpep is available as enteric-coated delayed-release capsules and as a powder for oral use. The enzyme units vary by strength to allow dose titration based on clinical need.

Specific strengths commonly available in capsules include:
- Zenpep capsules containing units equivalent to 3,000, 6,000, 12,000, 16,000, 20,000, 25,000, 36,000, 40,000 lipase units, each combined with corresponding protease and amylase units.
- Zenpep oral powder: typically dosed as a measured portion (e.g., one-fourth teaspoonful; approximately 0.7 g) for pediatric use in cystic fibrosis.

Dosages for Adults and Adolescents:
- Initial dosing for pancreatic exocrine insufficiency: lipase 500 units/kg orally per meal.
- Maintenance dosing: lipase 400 to 2,500 units/kg orally per meal; half-dose is administered with snacks.
- Maximum total daily lipase dose should not exceed 10,000 units/kg body weight.
- For chronic pancreatitis: 8,000 to 36,000 lipase USP units per meal orally, or 8,000 to 16,000 units every 2 hours in cases of pancreatectomy or duct obstruction.

Dosages for Pediatric Populations:
- Infants (<1 year): 2,000 to 4,000 units per 120 mL of formula, breast milk, or per breast-feeding.
- Children aged >1 to <4 years: initial 1,000 units/kg/meal, titrated to 1,000–2,500 units/kg/meal.
- Children ≥4 years: dosing generally follows adult regimens.
- In cystic fibrosis, the powder formulation is administered as one-fourth teaspoonful (0.7 g) with meals.

Specific Patient Populations:
- Patients post-pancreatectomy or with pancreatic duct obstruction may require dosing at 2-hour intervals.
- Patients with gastroesophageal reflux or gastric acidity often benefit from concomitant use of acid-suppressing agents such as proton pump inhibitors to optimize enzyme activity.
- Dose adjustments are important for patients with changes in body weight and in pediatric populations where growth status may influence enzyme requirements.
- Special caution is warranted in patients with known allergies to pork proteins, as pancrelipase is pork-derived.

Mechanism Of Action

Zenpep's active component is pancrelipase, a combination of digestive enzymes primarily consisting of lipase, protease, and amylase. These enzymes function by supplementing deficient pancreatic exocrine secretions, due to congenital or acquired pancreatic insufficiency.

Lipase catalyzes the hydrolysis of dietary triglycerides into monoglycerides and free fatty acids, which are absorbable forms of fat. Protease enzymes, including trypsin and chymotrypsin, break down proteins into smaller peptides and amino acids, facilitating protein absorption. Amylase catalyzes the hydrolysis of starch and carbohydrates into maltose and dextrins, enabling sugar absorption.

In patients with conditions like cystic fibrosis, chronic pancreatitis, or post-surgical pancreatic resection, endogenous pancreatic enzyme production is insufficient to digest fats, proteins, and carbohydrates, causing malabsorption, steatorrhea, malnutrition, and other complications. Oral administration of Zenpep delivers active enzymes directly to the duodenum and jejunum where digestion normally occurs. Enteric-coated capsules protect the enzymes from gastric acid degradation, ensuring that enzyme activity is preserved until reaching the higher pH environment of the small intestine.

Clinical studies have demonstrated that supplementation with pancrelipase-containing formulations improves nutrient absorption, decreases steatorrhea, supports healthy weight gain in pediatric populations, and improves clinical symptoms of pancreatic exocrine insufficiency. Compared with other pancreatic enzyme replacements such as Creon or Pancreaze, Zenpep provides similar enzyme compositions and efficacy but offers a range of dosage strengths allowing for individualized titration. Ongoing research supports the use of pancrelipase in optimizing digestion and improving quality of life in patients with pancreatic insufficiency.

Pharmacological Actions

Replacement of deficient pancreatic enzymes (lipase, protease, amylase) for digestive support.
Enhancement of fat digestion and absorption through lipase enzymatic activity.
Facilitation of protein digestion via protease activity.
Improvement of carbohydrate digestion by amylase enzymatic action.
Reduction of symptoms associated with pancreatic exocrine insufficiency such as steatorrhea and malnutrition.
Support of nutritional status and weight gain in individuals with cystic fibrosis or chronic pancreatitis.
Local enzymatic activity in the small bowel without systemic absorption.
Enzyme activity protected from gastric acid through enteric coating, facilitating delivery to the small intestine.
Improvement in quality of life via amelioration of digestive symptoms.
Dose titratable based on clinical response and patient-specific needs.
Treatment of malabsorption associated with surgical removal or dysfunction of the pancreas.

Therapeutic Or Clinical Uses

Treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
Management of chronic pancreatitis with impaired pancreatic enzyme secretion.
Replacement therapy following surgical pancreatectomy or pancreatic duct obstruction.
Improvement of fat, protein, and carbohydrate digestion in pancreatic insufficiency.
Reduction of malabsorption and steatorrhea symptoms.
Support for nutritional maintenance and growth, especially in pediatric patients.
Adjunct therapy in patients with pancreatic insufficiency due to cystic fibrosis, aiding in enhanced digestion and absorption.
Management of enzyme deficiency secondary to pancreatic inflammation or injury.
Use as part of comprehensive care in patients with pancreatic conditions causing digestive enzyme deficiency.
Enhancement of dietary nutrient uptake in patients unable to produce adequate pancreatic enzymes.

Side Or Adverse Effects

Gastrointestinal symptoms such as stomach pain, gas, vomiting, and diarrhea.
Rectal itching and other perianal irritation due to enzyme activity in stool.
Headache and dizziness reported in some patients.
Respiratory symptoms including runny or stuffy nose, cough, and sore throat.
Potential allergic reactions including hives, swelling of face, lips, tongue, or throat, and difficulty breathing.
Rare but serious risk of fibrosing colonopathy leading to bowel obstruction or strictures.
Changes in blood sugar levels may occur due to improved nutrient absorption.
Irritation of mucous membranes if powder contents come into direct contact with skin or respiratory tract.
Local irritation in the mouth if capsules are chewed or held in the mouth.
Potential weight loss or failure to grow in pediatric patients if enzyme replacement is inadequate.
Constipation or bloating in some individuals.
Potential for exacerbation of gastrointestinal symptoms if overdosed.
Possible hypersensitivity to pork proteins, the source of the enzymes.
Risk of aspiration or irritation if powder is inhaled accidentally.
Mild to moderate side effects common; severe adverse effects are rare but warrant urgent medical evaluation.

Precautions

Do not use if allergic to pork proteins due to risk of hypersensitivity reactions.
Monitor for signs of rare but serious bowel disorders such as severe abdominal pain, vomiting, bloating, diarrhea, or constipation.
Avoid crushing, chewing, or breaking capsules to prevent oral mucosal irritation and ensure intestinal enzyme delivery.
Avoid inhalation or skin contact with capsule powder to prevent respiratory and skin irritation.
Use caution in patients with a history of kidney disease, gout, or diabetes, as metabolic status may influence dosing.
Patients with intestinal blockage or scarring should inform their healthcare provider prior to use.
Not established as safe in pregnant or breastfeeding women; use only if clearly needed and prescribed by a doctor.
Dose adjustments necessary in pediatric populations and with changes in body weight.
Use caution in patients who have difficulty swallowing capsules; advise mixing contents with applesauce but not with infant formula or breast milk.
Concomitant use with acid-suppressing medication may be required to optimize enzyme efficacy.
Regular monitoring of nutritional status, weight, and growth in pediatric patients is advised.
Do not share medication between patients; use only under medical supervision for indicated conditions.
Careful follow-up needed to detect any signs of enzyme intolerance or treatment failure.
Patients should be educated on proper administration techniques to avoid adverse effects.
Adjust treatment regimen based on clinical response and symptom resolution.

Warnings

Contraindicated in patients with known allergy to pork proteins due to risk of anaphylaxis.
Risk of developing fibrosing colonopathy, a rare but serious bowel condition, mainly associated with high-dose, long-term use.
Discontinue and seek immediate medical attention if symptoms of bowel obstruction or severe gastrointestinal distress occur.
Avoid crushing or chewing capsules as this may cause mouth irritation and reduce drug efficacy.
The enzyme powder can cause respiratory tract irritation if inhaled accidentally.
Use cautiously in patients with a history of gastrointestinal tract scarring or strictures.
Pregnancy safety has not been established; weigh risks versus benefits before use.
Breastfeeding safety is unknown; inform healthcare provider before use during lactation.
Potential for severe allergic reactions necessitates readiness to manage anaphylaxis.
Patients should not discontinue therapy abruptly without medical advice.
Monitor for unusual gastrointestinal symptoms during therapy and report promptly.
Use in children requires careful dose titration and monitoring due to potential growth impact.
Do not mix contents of capsules with infant formula or breast milk to avoid enzyme inactivation.
Avoid inappropriate dosing that exceeds recommended maximum units to prevent adverse effects.
Failure to take with food may reduce drug effectiveness and lead to digestive symptoms.

Contraindication

Hypersensitivity or allergy to pork proteins or any component of pancrelipase preparations.
Known allergic reaction to pancrelipase or any constituent enzymes.
Patients with known or suspected fibrosing colonopathy may require cautious use or avoidance.
Not suitable for patients with complete obstruction of the gastrointestinal tract without surgical resolution.
Contraindicated in patients who have experienced prior severe adverse reactions to any pancreatic enzyme products.
Major caution in patients with known severe hypersensitivity to enzyme replacement therapies.
Contraindicated in individuals who cannot swallow capsules and refuse or are unable to use alternative administration methods.
Patients with exacerbated bowel obstruction or severe gastrointestinal inflammation may require alternative therapies.
Use contraindicated without appropriate medical supervision in infants under one year without assessment.
Contraindicated in patients with conditions leading to risk of aspiration if enzyme powder is inhaled.
Patients with documented allergy to excipients in the capsule or powder formulations.
Contraindicated if prescribed off-label without demonstrated pancreatic exocrine insufficiency.
Not recommended for use as a general nutritional supplement without medical justification.
Patients with severe liver disease may require caution due to altered digestion and metabolism.
Use contraindicated if patient develops allergy symptoms after initiation of therapy.

Drug Interactions

Concomitant use with acid-suppressing agents such as proton pump inhibitors (Nexium, Prilosec) or H2 blockers can improve Zenpep efficacy by reducing gastric acid degradation of enzymes.
Potential interaction with medications that alter gastrointestinal pH or motility may affect enzyme activity and digestion.
No significant systemic drug interactions due to minimal systemic absorption, but local GI tract interactions may occur.
Coadministration with antacids should be carefully managed to avoid changes in enzyme release timing.
Drugs that influence gastrointestinal transit time may modify enzyme exposure and effectiveness.
No known interactions with common antibiotics, but clinicians should evaluate patient-specific medication profiles.
Avoid mixing capsule contents with infant formula or breast milk that may alter enzyme activation; this can affect absorption of concurrently administered oral drugs.
Careful monitoring advised when used concomitantly with drugs affecting blood glucose, as improved digestion may alter glycemic control.
No reported significant interactions with vitamins or herbal supplements, though individual assessment is prudent.
No interaction identified with alcohol consumption, but alcohol may worsen pancreatic insufficiency symptoms.
No contraindications found with common respiratory or cardiovascular medications.
Multidrug regimens in cystic fibrosis patients should be reviewed for potential effects on digestion and enzyme performance.
Interactions with medications affecting bile secretion or lipid digestion should be considered due to additive or antagonistic effects.
Patients should report all concurrent medications and supplements to healthcare providers to ensure compatibility.
No known interaction with immunosuppressants commonly used in post-pancreatectomy or cystic fibrosis care.

Preparations Of The Drug

Enteric-coated delayed-release capsules containing pancrelipase enzyme units standardized by lipase activity.
Oral powder formulations designed for pediatric use, allowing mixing with soft foods for easier administration.
Multiple dosage strengths available to enable dose titration from low to high enzyme units depending on patient needs.
Capsules formulated to protect enzymes from gastric acid degradation and release them in the duodenum.
Powder form allowing direct administration or mixing with applesauce but not with formula or breast milk.
Available as prescription-only medication for pancreatic enzyme replacement therapy.
Supplied in bottles with moisture-absorbing packets to preserve enzyme stability.
Storage recommendations include protection from excessive heat and moisture to maintain enzymatic activity.
Packaging designed to keep bottles tightly closed when not in use to prevent moisture exposure.
Different branded preparations with comparable enzyme compositions include Creon, Pancreaze, and Pertzye.
Formulations developed to provide consistent lipase, protease, and amylase ratios per dose.
Available sizes accommodate both adult and pediatric dosing schedules.
Manufactured under strict quality control to ensure potency and batch-to-batch consistency.
Dosage forms intended to optimize patient adherence through ease of administration with meals.
Prescription labels and patient information leaflets provided to educate on proper dosing and handling.